Friday 16 October 2026
Export GLSI’s income statement to Excel — free account
Greenwich LifeSciences, Inc.
GLSI Healthcare Biotechnology
In the quarter to June 2026, EPS grew 10.0% and free cash flow grew 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.55
0.77
−5.03%
Follow GLSI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (986.31%) | (676.66%) | (3,068.35%) | (566.73%) |
+8 more TTM periods Free account |
|
| (374.46%) | (336.00%) | (376.92%) | (421.74%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(720.90%) | (422.57%) | (5,480.80%) | (929.56%) | |
Free Cash Flow per Share |
(0.85) | (0.88) | (0.73) | (0.63) | |
Free Cash Flow |
(12.49) | (12.78) | (9.91) | (8.59) | |
| Other line items | |||||
Cash ROIC |
(104.12%) | (81.02%) | (151.79%) | (143.37%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.56 | 0.57 | 0.51 | 0.42 | |
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.85) | (0.88) | (0.73) | (0.63) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates